Table 1. Patients’ clinical information.
| Clinical characteristics | n (%) | |
| Experimental group (N=160) | Control group (N=90) | |
| FIGO, the International Federation of Gynecology and Obstetrics. | ||
| Age (year) | ||
| Mean (range) | 55.7 (19−82) | 44.4 (20−81) |
| CA125 level before initial treatment (U/mL) | ||
| ≤35 | 39 (24.4) | 74 (82.2) |
| >35 | 121 (75.6) | 16 (17.8) |
| Ascites volume (mL) | ||
| <500 | 93 (58.1) | 89 (98.9) |
| ≥500 | 67 (41.9) | 1 (1.1) |
| Pathological typing | ||
| Serous | 126 (78.8) | 8 (8.9) |
| Mucinous | 10 (6.2) | 4 (4.4) |
| Endometrioid | 2 (1.3) | − |
| Clear cell-like | 17 (10.6) | − |
| Mature teratoma | − | 12 (13.3) |
| Chocolate cyst | − | 10 (11.1) |
| Fibro-theca cell tumor | − | 5 (5.6) |
| Fallopian mesangial cyst | − | 4 (4.4) |
| Serous mucinous
cystadenoma |
− | 4 (4.4) |
| Others (including 40
health females) |
5 (3.1) | 43 (47.8) |
| FIGO staging | ||
| I | 34 (21.3) | − |
| II | 21 (13.1) | − |
| III | 84 (52.5) | − |
| IV | 21 (13.1) | − |
| Grading | ||
| 1 | 9 (5.6) | − |
| 2 | 8 (5.0) | − |
| 3 | 127 (79.4) | − |
| Others | 16 (10.0) | − |